采用网络Meta分析和多标准决策分析(MCDA)模型对复方斑马龙胶囊的获益-风险进行评价。汇生口服液,和金龙胶囊辅助治疗原发性肝癌(PLC)。复方斑ataris胶囊的随机对照试验(RCT),汇生口服液,金龙胶囊治疗PLC的检索来自CNKI,万方,VIP,WebofScience,PubMed,科克伦图书馆采用R4.2进行网络荟萃分析,在此基础上通过间接比较获得了三种药物的作用值。基于收益-风险指数进行MCDA建立价值树。Hive3.2用于计算效益值,风险值,以及三种药物治疗PLC的获益风险值,并进行了敏感性分析,以评估结果的稳健性。采用OracleCrystalBall11.1对评价结果进行蒙特卡罗模拟优化。共纳入39项RCT。结果表明,复方斑潜鱼胶囊,汇生口服液,金龙胶囊联合肝动脉化疗栓塞术(TACE)的获益值分别为45、51和45,风险值分别为59、47和41,获益-风险值分别为52、49和43。复方Cantharis胶囊与回生口服液的获益-风险差异及[95CI]复方斑马龙胶囊vs金龙胶囊,汇生口服液与金龙胶囊的比较为3.00[-13.09,21.82],9.00[-4.39,24.62],和6.00[-8.84,20.28],分别。根据MCDA的结果,汇生口服液,金龙胶囊,复方斑ataris胶囊联合TACE治疗效果最大,最大的风险,和最佳的整体效益,分别。考虑到疗效和安全性,三种口服中成药联合TACE治疗PLC的优先顺序遵循复方斑ataris胶囊的趋势,汇生口服液,和金龙胶囊。
Network Meta-analysis and multi-criteria decision analysis(MCDA) model were performed to evaluate the benefit-risk of Compound Cantharis Capsules, Huisheng Oral Solution, and Jinlong Capsules in the adjuvant treatment of primary liver cancer(PLC). The randomized controlled trial(RCT) of Compound Cantharis Capsules, Huisheng Oral Solution, and Jinlong Capsules in treating PLC were retrieved from CNKI, Wanfang, VIP, Web of Science, PubMed, and Cochrane Library. R 4.2 was employed to conduct a network Meta-analysis, on the basis of which the effect values of the three medicines were obtained by indirect comparison. MCDA was performed to establish the value tree based on the benefit-risk indexes. Hiview 3.2 was used to calculate the benefit values, risk values, and benefit-risk values of the three medicines in treating PLC, and a sensitivity analysis was carried out to evaluate the robustness of the results. Oracle Crystal Ball 11.1 was employed to optimize the evaluation results by Monte Carlo simulation. A total of 39 RCTs were included. The results showed that Compound Cantharis Capsules, Huisheng Oral Solution, and Jinlong Capsules combined with transcatheter arterial chemoembolization(TACE) had the benefit values of 45, 51 and 45, the risk values of 59, 47, and 41, and the benefit-risk values of 52, 49, and 43, respectively. The benefit-risk differences and [95%CI] of Compound Cantharis Capsules vs Huisheng Oral Solution, Compound Cantharis Capsules vs Jinlong Capsules, and Huisheng Oral Solution vs Jinlong Capsules were 3.00[-13.09, 21.82], 9.00[-4.39, 24.62], and 6.00[-8.84, 20.28], respectively. Based on the results of MCDA, Huisheng Oral Solution, Jinlong Capsules, and Compound Cantharis Capsules combined with TACE had the greatest benefit, the greatest risk, and the best overall benefit, respectively. Considering the efficacy and safety, the priority of the three oral Chinese patent medicines combined with TACE for treating PLC followed the trend of Compound Cantharis Capsules, Huisheng Oral Solution, and Jinlong Capsules.